Adhesive capsaicin 8% patch for improved control of pain caused by chemotherapy-induced peripheral neuropathy in patients with multiple myeloma: A single-centre, seven-case series

J Oncol Pharm Pract. 2024 Jun;30(4):752-758. doi: 10.1177/10781552241230887. Epub 2024 Feb 28.

Abstract

Background: Capsaicin is a highly selective agonist of the transient receptor potential vanilloid 1. The adhesive capsaicin patch provides a high capsaicin concentration (8%) directly in the painful area - its efficacy in benign peripheral neuropathic pain (diabetic neuropathy or postherpetic neuralgia) has recently been described in the literature. However, there is scant evidence of its efficacy in chemotherapy-induced peripheral neuropathy (CIPN). This is a concern for patients with multiple myeloma, who suffer from peripheral neuropathic pain induced by first-line treatments (bortezomib or thalidomide).

Aim: To describe improved control of CIPN in patients with multiple myeloma using adhesive capsaicin 8% patch.

Methods: We opted for a retrospective observational case series. Between October 2017 and October 2020, we collected clinical data from adult multiple myeloma patients affected by CIPN who were administered the capsaicin 8% patch in our palliative care outpatient clinic. We compiled Numerical Pain Rating Scale (NPRS) scores, patients' medication needs and performance status before and after patch application.

Results: Two women and five men with an average age of 62.85 years received bortezomib. Two patients (28.57% of the sample) also received thalidomide. The average NPRS score before patch application was 6.42/10. Five of the seven patients (71.42%) received a mean daily oral morphine dose of 52.85 mg/day, five (71.42%) received gabapentinoids and one (14.28%) received antidepressants. The average NPRS score decreased to 4/10 seven days after patch application, while the mean daily oral morphine dose remained stable. Performance status improved slightly in two patients (28.57%) and remained stable in the rest. One patient (14.28%) required an extra analgesic dose during patch application.

Conclusions: Capsaicin 8% patch application appears to reduce pain intensity in patients with multiple myeloma suffering from CIPN.

Keywords: Capsaicin; chemotherapy-induced peripheral neuropathy; multiple myeloma; neuropathic pain; palliative care.

Publication types

  • Observational Study

MeSH terms

  • Aged
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects
  • Bortezomib* / administration & dosage
  • Bortezomib* / adverse effects
  • Bortezomib* / therapeutic use
  • Capsaicin* / administration & dosage
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma* / drug therapy
  • Neuralgia / chemically induced
  • Neuralgia / drug therapy
  • Pain Measurement
  • Peripheral Nervous System Diseases / chemically induced
  • Peripheral Nervous System Diseases / drug therapy
  • Retrospective Studies
  • Thalidomide / administration & dosage
  • Thalidomide / adverse effects
  • Thalidomide / therapeutic use
  • Transdermal Patch

Substances

  • Capsaicin
  • Bortezomib
  • Antineoplastic Agents
  • Thalidomide